Species-specific restriction of Apobec3-mediated hypermutation

被引:63
作者
Browne, Edward P. [1 ,3 ,4 ]
Littman, Dan R. [1 ,2 ,3 ,4 ]
机构
[1] NYU, Sch Med, Kimmel Ctr Biol & Med, Skirball Inst, New York, NY 10016 USA
[2] NYU, Sch Med, Howard Hughes Med Inst, New York, NY 10016 USA
[3] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA
[4] NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA
关键词
D O I
10.1128/JVI.01371-07
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Apobec proteins are a family of cellular cytidine deaminases, among which several members have been shown to have potent antiviral properties. This antiviral activity is associated with the ability to cause hypermutation of retroviral cDNA. However, recent research has indicated that Apobec proteins are also able to inhibit retroviruses by other mechanisms that are independent of their deaminase activity. We have compared the antiviral activities of human and murine Apobec3 (A3) proteins, and we have found that, consistent with previous reports, human immunodeficiency virus (HIV) is able to resist human A3G but is sensitive to murine A3, whereas murine leukemia virus (MLV) is relatively resistant to murine A3 (mA3) but sensitive to human A3G. In contrast to previous studies, we observed that mA3 is packaged efficiently into MLV particles. The C-terminal cytidine deaminase domain (CDD2) is required for packaging of mA3 into MLV particles, and packaging did not depend on the MLV viral RNA. However, mA3 packed into MLV particles failed to cause hypermutation of viral DNA, indicating that its deaminase activity is blocked or inhibited. hA3G also caused significantly less hypermutation of MLV than of HIV DNA. Both mA3 and the splice variant mA3 Delta 5 exhibited some residual antiviral activity against MLV and caused a reduction in the ability of MLV particles to generate reverse transcription products. These results suggest that MLV has evolved specific mechanisms to block the ability of Apobec proteins to mediate deaminase-dependent hypermutation.
引用
收藏
页码:1305 / 1313
页数:9
相关论文
共 33 条
[1]   Murine retrovirus escapes from murine APOBEC3 via two distinct novel mechanisms [J].
Abudu, Aierken ;
Takaori-Kondo, Akifumi ;
Izumi, Taisuke ;
Shirakawa, Kotaro ;
Kobayashi, Masayuki ;
Sasada, Amane ;
Fukunaga, Keiko ;
Uchiyama, Takashi .
CURRENT BIOLOGY, 2006, 16 (15) :1565-1570
[2]   Antiviral potency of APOBEC proteins does not correlate with cytidine deamination [J].
Bishop, Kate N. ;
Holmes, Rebecca K. ;
Malim, Michael H. .
JOURNAL OF VIROLOGY, 2006, 80 (17) :8450-8458
[3]   Cytidine deamination of retroviral DNA by diverse APOBEC proteins [J].
Bishop, KN ;
Holmes, RK ;
Sheehy, AM ;
Davidson, NO ;
Cho, SJ ;
Malim, MH .
CURRENT BIOLOGY, 2004, 14 (15) :1392-1396
[4]   APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons [J].
Chen, H ;
Lilley, CE ;
Yu, Q ;
Lee, DV ;
Chou, J ;
Narvaiza, I ;
Landau, NR ;
Weitzman, MD .
CURRENT BIOLOGY, 2006, 16 (05) :480-485
[5]   Multifaceted antiviral actions of APOBEC3 cytidine deaminases [J].
Chiu, Ya-Lin ;
Greene, Warner C. .
TRENDS IN IMMUNOLOGY, 2006, 27 (06) :291-297
[6]   RETRACTED: Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells (Retracted Article. See vol 466, pg 276, 2010) [J].
Chiu, YL ;
Soros, VB ;
Kreisberg, JF ;
Stopak, K ;
Yonemoto, W ;
Greene, WC .
NATURE, 2005, 435 (7038) :108-114
[7]   Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion [J].
Doehle, BP ;
Schäfer, A ;
Wiegand, HL ;
Bogerd, HP ;
Cullen, BR .
JOURNAL OF VIROLOGY, 2005, 79 (13) :8201-8207
[8]   APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses [J].
Esnault, C ;
Heidmann, O ;
Delebecque, F ;
Dewannieux, M ;
Ribet, D ;
Hance, AJ ;
Heidmann, T ;
Schwartz, O .
NATURE, 2005, 433 (7024) :430-433
[9]  
GUO F, 2007, J VIROL
[10]   The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain [J].
Haché, G ;
Liddament, MT ;
Harris, RS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (12) :10920-10924